natgillin/translations-raw huggingface dataset:
Having regard to Regulation (EC) No 1107/2009 of the European Parliament and of the Council of 21 October 2009 concerning the placing of plant protection products on the market and repealing Council Directives 79/117/EEC and 91/414/EEC [1], and in particular the first paragraph of Article 17 thereof,
ob upoštevanju Uredbe (ES) št. 1107/2009 Evropskega parlamenta in Sveta z dne 21. oktobra 2009 o dajanju fitofarmacevtskih sredstev v promet in razveljavitvi direktiv Sveta 79/117/EGS in 91/414/EGS [1] in zlasti prvega odstavka člena 17 Uredbe,
Part A of the Annex to Commission Implementing Regulation (EU) No 540/2011 [2] sets out the active substances deemed to have been approved under Regulation (EC) No 1107/2009.
Del A Priloge k Izvedbeni uredbi Komisije (EU) št. 540/2011 [2] določa aktivne snovi, ki se štejejo za odobrene v skladu z Uredbo (ES) št. 1107/2009.
The approval periods of the active substances carfentrazone ethyl, cyazofamid, ethofumesate, fenamidone, foramsulfuron, imazamox, isoxaflutole, linuron, mesotrione, oxasulfuron, pendimethalin and trifloxystrobin were derogated from by Commission Regulation (EU) No 823/2012 [3].
Z Uredbo Komisije (EU) št. 823/2012 [3] je bilo odobreno odstopanje za obdobja odobritve aktivnih snovi karfentrazon-etil, ciazofamid, etofumesat, fenamidon, foramsulfuron, imazamoks, izoksaflutol, linuron, mezotrion, oksasulfuron, pendimetalin in trifloksistrobin.
The approval of those substances will expire on 31 July 2016.
Odobritev navedenih snovi bo prenehala veljati 31. julija 2016.
The approval periods of the active substances 2,4-DB, beta-cyfluthrin, Coniothyrium minitans Strain CON/M/91-08 (DSM 9660), deltamethrin, dimethenamid-P, flufenacet, flurtamone, fosthiazate, iodosulfuron, iprodione, maleic hydrazide, picoxystrobin and silthiofam were derogated from by Regulation (EU) No 823/2012.
Z Uredbo (EU) št. 823/2012 je bilo odobreno odstopanje za obdobja odobritve aktivnih snovi 2,4-DB, beta-ciflutrin, Coniothyrium minitans sev CON/M/91–08 (DSM 9660), deltametrin, dimetenamid-p, flufenacet, flurtamon, fostiazat, jodosulfuron, iprodion, malein hidrazid, pikoksistrobin in siltiofam.
The approval of these substances will expire on 31 October 2016.
Odobritev navedenih snovi bo prenehala veljati 31. oktobra 2016.
Applications for the renewal of the approval of those substances were submitted in accordance with Commission Implementing Regulation (EU) No 844/2012 [4].
Zahtevki za obnovitev odobritve navedenih snovi so bili vloženi v skladu z Izvedbeno uredbo Komisije (EU) št. 844/2012 [4].
Due to the fact that the assessment of the substances has been delayed for reasons beyond the control of the applicants, the approvals of those active substances are likely to expire before a decision has been taken on their renewal.
Ker se je ocenjevanje snovi zavleklo iz razlogov, na katere vložniki ne morejo vplivati, obstaja možnost, da bodo odobritve navedenih aktivnih snovi potekle pred sprejetjem sklepa o njihovi obnovitvi.
In view of the aim of the first paragraph of Article 17 of Regulation (EC) No 1107/2009, as regards cases where the Commission will adopt a Regulation providing that the approval of an active substance referred to in the Annex to this Regulation is not renewed because the approval criteria are not satisfied, the Commission will set the expiry date at the same date as before this Regulation or at the date of the entry into force of the Regulation providing that the approval of the active substance is not renewed, whichever date is later.
Glede na cilj prvega odstavka člena 17 Uredbe (ES) št. 1107/2009 v zvezi s primeri, v katerih Komisija sprejme uredbo, ki določa, da se odobritev aktivne snovi iz Priloge k tej uredbi ne obnovi, ker merila za odobritev niso izpolnjena, Komisija določi isti datum veljavnosti kot pred to uredbo ali datum začetka veljavnosti Uredbe, ki določa, da se odobritev aktivne snovi ne obnovi, odvisno od tega, kateri datum je poznejši.
As regards cases where the Commission will adopt a Regulation providing for the renewal of an active substance referred to in the Annex to this Regulation, the Commission will endeavour to set, as appropriate under the circumstances, the earliest possible application date.
V zvezi s primeri, v katerih Komisija sprejme uredbo o obnovitvi odobritve aktivne snovi iz Priloge k tej uredbi, bo Komisija poskusila določiti, kot je ustrezno v danih okoliščinah, najzgodnejši datum začetka uporabe.
in the sixth column, expiration of approval, of row 29, Ethofumesate, the date is replaced by ‘31 July 2017’;
v šestem stolpcu vrstice 29 za etofumesat se datum poteka odobritve nadomesti z „31. julij 2017“;
in the sixth column, expiration of approval, of row 40, Deltamethrin, the date is replaced by ‘31 October 2017’;
v šestem stolpcu vrstice 40 za deltametrin se datum poteka odobritve nadomesti z „31. oktober 2017“;
in the sixth column, expiration of approval, of row 41, Imazamox, the date is replaced by ‘31 July 2017’;
v šestem stolpcu vrstice 41 za imazamoks se datum poteka odobritve nadomesti z „31. julij 2017“;
in the sixth column, expiration of approval, of row 42, Oxasulfuron, the date is replaced by ‘31 July 2017’;
v šestem stolpcu vrstice 42 za oksasulfuron se datum poteka odobritve nadomesti z „31. julij 2017“;
in the sixth column, expiration of approval, of row 44, Foramsulfuron, the date is replaced by ‘31 July 2017’;
v šestem stolpcu vrstice 44 za foramsulfuron se datum poteka odobritve nadomesti z „31. julij 2017“;
in the sixth column, expiration of approval, of row 46, Cyazofamid, the date is replaced by ‘31 July 2017’;
v šestem stolpcu vrstice 46 za ciazofamid se datum poteka odobritve nadomesti z „31. julij 2017“;
in the sixth column, expiration of approval, of row 47, 2,4-DB, the date is replaced by ‘31 October 2017’;
v šestem stolpcu vrstice 47 za 2,4-DB se datum poteka odobritve nadomesti z „31. oktober 2017“;
in the sixth column, expiration of approval, of row 48, Beta-cyfluthrin, the date is replaced by ‘31 October 2017’;
v šestem stolpcu vrstice 48 za beta-ciflutrin se datum poteka odobritve nadomesti z „31. oktober 2017“;
in the sixth column, expiration of approval, of row 50, Iprodione, the date is replaced by ‘31 October 2017’;
v šestem stolpcu vrstice 50 za iprodion se datum poteka odobritve nadomesti z „31. oktober 2017“;
in the sixth column, expiration of approval, of row 51, Linuron, the date is replaced by ‘31 July 2017’;
v šestem stolpcu vrstice 51 za linuron se datum poteka odobritve nadomesti z „31. julij 2017“;
in the sixth column, expiration of approval, of row 52, Maleic hydrazide, the date is replaced by ‘31 October 2017’;
v šestem stolpcu vrstice 52 za malein hidrazid se datum poteka odobritve nadomesti z „31. oktober 2017“;
in the sixth column, expiration of approval, of row 53, Pendimethalin, the date is replaced by ‘31 July 2017’;
v šestem stolpcu vrstice 53 za pendimetalin se datum poteka odobritve nadomesti z „31. julij 2017“;
in the sixth column, expiration of approval, of row 59, Trifloxystrobin, the date is replaced by ‘31 July 2017’;
v šestem stolpcu vrstice 59 za trifloksistrobin se datum poteka odobritve nadomesti z „31. julij 2017“;
in the sixth column, expiration of approval, of row 60, Carfentrazone ethyl, the date is replaced by ‘31 July 2017’;
v šestem stolpcu vrstice 60 za karfentrazon-etil se datum poteka odobritve nadomesti z „31. julij 2017“;
in the sixth column, expiration of approval, of row 61, Mesotrione, the date is replaced by ‘31 July 2017’;
v šestem stolpcu vrstice 61 za mezotrion se datum poteka odobritve nadomesti z „31. julij 2017“;
in the sixth column, expiration of approval, of row 62, Fenamidone, the date is replaced by ‘31 July 2017’;
v šestem stolpcu vrstice 62 za fenamidon se datum poteka odobritve nadomesti z „31. julij 2017“;
in the sixth column, expiration of approval, of row 63, Isoxaflutole, the date is replaced by ‘31 July 2017’;
v šestem stolpcu vrstice 63 za izoksaflutol se datum poteka odobritve nadomesti z „31. julij 2017“;
in the sixth column, expiration of approval, of row 64, Flurtamone, the date is replaced by ‘31 October 2017’;
v šestem stolpcu vrstice 64 za flurtamon se datum poteka odobritve nadomesti z „31. oktober 2017“;
in the sixth column, expiration of approval, of row 65, Flufenacet, the date is replaced by ‘31 October 2017’;
v šestem stolpcu vrstice 65 za flufenacet se datum poteka odobritve nadomesti z „31. oktober 2017“;
in the sixth column, expiration of approval, of row 66, Iodosulfuron, the date is replaced by ‘31 October 2017’;
v šestem stolpcu vrstice 66 za jodosulfuron se datum poteka odobritve nadomesti z „31. oktober 2017“;
in the sixth column, expiration of approval, of row 67, Dimethenamid-P, the date is replaced by ‘31 October 2017’;
v šestem stolpcu vrstice 67 za dimetenamid-p se datum poteka odobritve nadomesti z „31. oktober 2017“;
in the sixth column, expiration of approval, of row 68, Picoxystrobin, the date is replaced by ‘31 October 2017’;
v šestem stolpcu vrstice 68 za pikoksistrobin se datum poteka odobritve nadomesti z „31. oktober 2017“;
in the sixth column, expiration of approval, of row 69, Fosthiazate, the date is replaced by ‘31 October 2017’;
v šestem stolpcu vrstice 69 za fostiazat se datum poteka odobritve nadomesti z „31. oktober 2017“;
in the sixth column, expiration of approval, of row 70, Silthiofam, the date is replaced by ‘31 October 2017’;
v šestem stolpcu vrstice 70 za siltiofam se datum poteka odobritve nadomesti z „31. oktober 2017“;
in the sixth column, expiration of approval, of row 71, Coniothyrium minitans Strain CON/M/91-08 (DSM 9660), the date is replaced by ‘31 October 2017’.
v šestem stolpcu vrstice 71 za Coniothyrium minitans sev CON/M/91-08 (DSM 9660) se datum poteka odobritve nadomesti z „31. oktober 2017“.
Commission Implementing Regulation (EU) 2016/951
Izvedbena uredba Komisije (EU) 2016/951
approving the low-risk active substance Trichoderma atroviride strain SC1, in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of plant protection products on the market, and amending the Annex to Commission Implementing Regulation (EU) No 540/2011
o odobritvi aktivne snovi z majhnim tveganjem Trichoderma atroviride, sev SC1, v skladu z Uredbo (ES) št. 1107/2009 Evropskega parlamenta in Sveta o dajanju fitofarmacevtskih sredstev v promet ter o spremembi Priloge k Izvedbeni uredbi Komisije (EU) št. 540/2011
Having regard to Regulation (EC) No 1107/2009 of the European Parliament and of the Council of 21 October 2009 concerning the placing of plant protection products on the market and repealing Council Directives 79/117/EEC and 91/414/EEC [1], and in particular Article 22(1) in conjunction with Article 13(2) thereof,
ob upoštevanju Uredbe (ES) št. 1107/2009 Evropskega parlamenta in Sveta z dne 21. oktobra 2009 o dajanju fitofarmacevtskih sredstev v promet in razveljavitvi direktiv Sveta 79/117/EGS in 91/414/EGS [1] in zlasti člena 22(1) v povezavi s členom 13(2) Uredbe,
In accordance with Article 7(1) of Regulation (EC) No 1107/2009, France received on 6 November 2012 an application from BI-PA NV for the approval of the active substance Trichoderma atroviride strain SC1.
V skladu s členom 7(1) Uredbe (ES) št. 1107/2009 je Francija 6. novembra 2012 prejela zahtevek družbe BI-PA NV za odobritev aktivne snovi Trichoderma atroviride, sev SC1.
In accordance with Article 9(3) of that Regulation, France, as rapporteur Member State, notified the Commission on 5 February 2013 of the admissibility of the application.
V skladu s členom 9(3) navedene uredbe je Francija kot država članica poročevalka 5. februarja 2013 obvestila Komisijo o dopustnosti zahtevka.
On 27 May 2014, the rapporteur Member State submitted a draft assessment report to the Commission with a copy to the European Food Safety Authority (hereinafter ‘the Authority’), assessing whether that active substance can be expected to meet the approval criteria provided for in Article 4 of Regulation (EC) No 1107/2009.
Država članica poročevalka je 27. maja 2014 Komisiji predložila osnutek poročila o oceni, pri čemer je en izvod poslala Evropski agenciji za varnost hrane (v nadaljnjem besedilu: Agencija), v katerem je ocenila, ali se za navedeno aktivno snov lahko pričakuje, da bo izpolnjevala merila za odobritev iz člena 4 Uredbe (ES) št. 1107/2009.
The assessment of the additional information by the rapporteur Member State was submitted to the Authority in the format of an updated draft assessment report in February 2015.
Država članica poročevalka je februarja 2015 Agenciji predložila oceno dodatnih informacij v obliki posodobljenega osnutka poročila o oceni.
On 21 April 2015 the Authority communicated to the applicant, the Member States and the Commission its conclusion on whether the active substance Trichoderma atroviride strain SC1 can be expected to meet the approval criteria provided for in Article 4 of Regulation (EC) No 1107/2009 [2].
Agencija je 21. aprila 2015 vložniku, državam članicam in Komisiji poslala svoj sklep o tem, ali se za aktivno snov Trichoderma atroviride, sev SC1, lahko pričakuje, da bo izpolnjevala merila za odobritev iz člena 4 Uredbe (ES) št. 1107/2009 [2].
On 10 December 2015 the Commission presented to the Standing Committee on Plants, Animals, Food and Feed the review report for Trichoderma atroviride strain SC1 and a draft Regulation providing that Trichoderma atroviride strain SC1 is approved.
Komisija je 10. decembra 2015 Stalnemu odboru za rastline, živali, hrano in krmo predložila poročilo o pregledu snovi Trichoderma atroviride, sev SC1, in osnutek uredbe o odobritvi snovi Trichoderma atroviride, sev SC1.
It is therefore appropriate to approve Trichoderma atroviride strain SC1.
Zato je primerno odobriti snov Trichoderma atroviride, sev SC1.
The Commission further considers that Trichoderma atroviride strain SC1 is a low-risk active substance pursuant to Article 22 of Regulation (EC) No 1107/2009.
Vendar pa Komisija meni, da je snov Trichoderma atroviride, sev SC1, aktivna snov z majhnim tveganjem v skladu s členom 22 Uredbe (ES) št. 1107/2009.
Trichoderma atroviride strain SC1 is not a substance of concern and fulfils the conditions set in point 5 of Annex II to Regulation (EC) No 1107/2009.
Trichoderma atroviride, sev SC1, ni problematična snov in izpolnjuje pogoje iz točke 5 Priloge II k Uredbi (ES) št. 1107/2009.
Trichoderma atroviride strain SC1 is a wild-type strain isolated from decaying hazelnut wood in Italy.
Trichoderma atroviride, sev SC1, je sev divjega tipa, izoliran iz razpadajočega lešnikovega lesa v Italiji.
It is not pathogenic or virulent to humans or animals.
Ni patogen ali virulenten za ljudi ali živali.
It is therefore appropriate to approve Trichoderma atroviride strain SC1 as a low-risk substance for a period of 15 years.
Zato je primerno odobriti snov Trichoderma atroviride, sev SC1, kot snov z majhnim tveganjem za obdobje 15 let.
Approval of a low-risk active substance
Odobritev aktivne snovi z majhnim tveganjem
The active substance Trichoderma atroviride strain SC1, as specified in Annex I, is approved subject to the conditions laid down in that Annex.
Aktivna snov Trichoderma atroviride, sev SC1, kot je opredeljena v Prilogi I, se odobri pod pogoji iz navedene priloge.
Specific provisions
Trichoderma atroviride, sev SC1
Trichoderma atroviride strain SC1
Referenčna številka CBS 122089 v zbirki „Centraalbureau voor Schimmelcultures (CBS)“ v Utrechtu, Nizozemska
Accession number CBS 122089 in the collection of the Centraalbureau voor Schimmelcultures (CBS) in Utrecht, The Netherland
št.
minimum concentration 1 × 1010 CFU/g
najnižja koncentracija 1 × 1010 CFU/g
6 July 2016
6. julij 2016
6 July 2031
6. julij 2031
For the implementation of the uniform principles as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the review report on Trichoderma atroviride strain SC1, and in particular Appendices I and II thereof, shall be taken into account.
Za izvajanje enotnih načel iz člena 29(6) Uredbe (ES) št. 1107/2009 se upoštevajo ugotovitve iz poročila o pregledu snovi Trichoderma atroviride, sev SC1, ter zlasti dodatka I in II k poročilu.
In this overall assessment Member States shall pay particular attention to the protection of operators and workers, taking into account that microorganisms are considered as potential sensitizers.
V tej celoviti oceni morajo biti države članice zlasti pozorne na zaščito izvajalcev in delavcev ob upoštevanju, da mikroorganizmi lahko povzročajo preobčutljivost.
Strict maintenance of environmental conditions and quality control analysis during the manufacturing process shall be assured by the producer.
Proizvajalec zagotovi strogo vzdrževanje okoljskih pogojev in analize nadzora kakovosti med proizvodnim postopkom.
In Part D of the Annex to Implementing Regulation (EU) No 540/2011, the following entry is added:
V delu D Priloge k Izvedbeni uredbi (EU) št. 540/2011 se doda naslednji vnos:
For the implementation of the uniform principles as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the review report on Trichoderma atroviride strain SC1, and in particular Appendices I and II thereof, shall be taken into account.
Za izvajanje enotnih načel iz člena 29(6) Uredbe (ES) št. 1107/2009 se upoštevajo ugotovitve iz poročila o pregledu snovi Trichoderma atroviride, sev SC1, ter zlasti dodatka I in II k poročilu.
Strict maintenance of environmental conditions and quality control analysis during the manufacturing process shall be assured by the producer.’
Proizvajalec zagotovi strogo vzdrževanje okoljskih pogojev in analize nadzora kakovosti med proizvodnim postopkom.“
Commission Implementing Regulation (EU) 2016/952
Izvedbena uredba Komisije (EU) 2016/952
approving the low-risk active substance Saccharomyces cerevisiae strain LAS02 in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of plant protection products on the market, and amending the Annex to Commission Implementing Regulation (EU) No 540/2011
o odobritvi aktivne snovi z majhnim tveganjem Saccharomyces cerevisiae, sev LAS02, v skladu z Uredbo (ES) št. 1107/2009 Evropskega parlamenta in Sveta o dajanju fitofarmacevtskih sredstev v promet ter o spremembi Priloge k Izvedbeni uredbi Komisije (EU) št. 540/2011
In accordance with Article 7(1) of Regulation (EC) No 1107/2009, France received on 9 April 2013 an application from Agrolevures et Dérivés for the approval of the active substance Saccharomyces cerevisiae strain LAS02.
V skladu s členom 7(1) Uredbe (ES) št. 1107/2009 je Francija 9. aprila 2013 prejela zahtevek družbe Agrolevures et Dérivés za odobritev aktivne snovi Saccharomyces cerevisiae, sev LAS02.
In accordance with Article 9(3) of that Regulation, France, as rapporteur Member State, notified the applicant, the other Member States, the Commission and the European Food Safety Authority (hereinafter ‘the Authority’) of the admissibility of the application on 15 October 2013.
V skladu s členom 9(3) navedene uredbe je Francija kot država članica poročevalka 15. oktobra 2013 obvestila vložnika, druge države članice, Komisijo in Evropsko agencijo za varnost hrane (v nadaljnjem besedilu: Agencija) o dopustnosti zahtevka.
On 4 December 2014, the rapporteur Member State submitted a draft assessment report to the Commission with a copy to the Authority, assessing whether that active substance can be expected to meet the approval criteria provided for in Article 4 of Regulation (EC) No 1107/2009.
Država članica poročevalka je 4. decembra 2014 Komisiji predložila osnutek poročila o oceni, pri čemer je en izvod poslala Agenciji, v katerem je ocenila, ali se za navedeno aktivno snov lahko pričakuje, da bo izpolnjevala merila za odobritev iz člena 4 Uredbe (ES) št. 1107/2009.
The assessment of the additional information by the rapporteur Member State was submitted to the Authority in the format of an updated draft assessment report on 14 September 2015.
Država članica poročevalka je 14. septembra 2015 Agenciji predložila oceno dodatnih informacij v obliki posodobljenega osnutka poročila o oceni.
On 3 December 2015, the Authority communicated to the applicant, the Member States and the Commission its conclusion on whether the active substance Saccharomyces cerevisiae strain LAS02 can be expected to meet the approval criteria provided for in Article 4 of Regulation (EC) No 1107/2009 [2].
Agencija je 3. decembra 2015 vložniku, državam članicam in Komisiji poslala svoj sklep o tem, ali se za aktivno snov Saccharomyces cerevisiae, sev LAS02, lahko pričakuje, da bo izpolnjevala merila za odobritev iz člena 4 Uredbe (ES) št. 1107/2009 [2].
On 7 March 2016, the Commission presented to the Standing Committee on Plants, Animals, Food and Feed the review report for Saccharomyces cerevisiae strain LAS02 and a draft Regulation providing that Saccharomyces cerevisiae strain LAS02 is approved as a low-risk active substance.
Komisija je 7. marca 2016 Stalnemu odboru za rastline, živali, hrano in krmo predložila poročilo o pregledu snovi Saccharomyces cerevisiae, sev LAS02, in osnutek uredbe o odobritvi snovi Saccharomyces cerevisiae, sev LAS02, kot aktivne snovi z majhnim tveganjem.
It has been established with respect to one or more representative uses of at least one plant protection product containing the active substance, and in particular the uses which were examined and detailed in the review report, that the approval criteria provided for in Article 4 of Regulation (EC) No 1107/2009 are satisfied.
V zvezi z eno ali več reprezentativnimi uporabami vsaj enega fitofarmacevtskega sredstva, ki vsebuje aktivno snov, zlasti v zvezi z uporabami, ki so bile proučene in podrobno navedene v poročilu Komisije o pregledu, je bilo ugotovljeno, da so merila za odobritev iz člena 4 Uredbe (ES) št. 1107/2009 izpolnjena.
It is therefore appropriate to approve Saccharomyces cerevisiae strain LAS02.
Zato je primerno odobriti snov Saccharomyces cerevisiae, sev LAS02.
The Commission further considers that Saccharomyces cerevisiae strain LAS02 is a low-risk active substance pursuant to Article 22 of Regulation (EC) No 1107/2009.
Vendar pa Komisija meni, da je snov Saccharomyces cerevisiae, sev LAS02, aktivna snov z majhnim tveganjem v skladu s členom 22 Uredbe (ES) št. 1107/2009.
Saccharomyces cerevisiae strain LAS02 is not a substance of concern and fulfils the conditions set in point 5 of Annex II to Regulation (EC) No 1107/2009.
Saccharomyces cerevisiae, sev LAS02, ni problematična snov in izpolnjuje pogoje iz točke 5 Priloge II k Uredbi (ES) št. 1107/2009.
Saccharomyces cerevisiae strain LAS02 is a naturally occurring yeast, which is widely used in food.
Saccharomyces cerevisiae, sev LAS02, je naravni kvas, ki se splošno uporablja v živilih.
It is also widely present in the environment.
Prav tako je splošno prisoten v okolju.
It is therefore appropriate to approve Saccharomyces cerevisiae strain LAS02 as a low-risk substance for a period of 15 years.
Zato je primerno odobriti snov Saccharomyces cerevisiae, sev LAS02, kot snov z majhnim tveganjem za obdobje 15 let.
The active substance Saccharomyces cerevisiae strain LAS02, as specified in Annex I, is approved subject to the conditions laid down in that Annex.
Aktivna snov Saccharomyces cerevisiae, sev LAS02, kot je opredeljena v Prilogi I, se odobri pod pogoji iz navedene priloge.
Specific provisions
Saccharomyces cerevisiae, sev LAS02
Saccharomyces cerevisae strain LAS02
Referenčna številka v zbirki „Collection Nationale de Cultures de Microorganismes“ (CNCM) inštituta Pasteur: CNCM I-3936
Accession number in the collection of the ‘Collection Nationale de Cultures de Microorganismes’ (CNCM) of the Pasteur Institute: CNCM I-3936
ni relevantno
Not applicable
najnižja koncentracija: 1 × 1013 CFU/kg
Minimum concentration: 1 × 1013 CFU/kg
6. julij 2016
6 July 2016
6. julij 2031
6 July 2031
Za izvajanje enotnih načel iz člena 29(6) Uredbe (ES) št. 1107/2009 se upoštevajo ugotovitve iz poročila o pregledu snovi Saccharomyces cerevisiae, sev LAS02, ter zlasti dodatka I in II k poročilu.